Changes in US stocks | Clinical-stage biotechnology company Aspen Neuroscience (ASPE.US)'s stock price fell more than 17% after entering the US stock market

The Zhitong Finance App learned that on Friday, Aspen Neuroscience (ASPE.US) entered the US stock market. As of press release, the stock had fallen more than 17% to $12.345. The IPO price is $15. Aspen Neuroscience is a clinical-stage biotechnology company headquartered in San Diego, California, USA. It was founded in 2018 and focuses on developing innovative treatments for neurodegenerative diseases such as Parkinson's disease using stem cell technology. The company's core product, sasineprocel (ANPD001), is a stem cell therapy using the patient's own cells. It aims to improve motor function by transplanting new nerve cells to replace damaged or lost dopamine neurons in Parkinson's disease patients. The treatment is currently in phase I/IIa clinical trial, and has obtained fast-track qualification and advanced regenerative medicine certification from the US Food and Drug Administration (FDA). The company plans to start patient administration in phase III clinical trials in the second half of 2027.